Physician profile
William J Mccrary
NPI 1780818930
$2,533.91
in general payments reported to CMS, 2019-2025
31 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $158 · 2021: $439 · 2022: $385 · 2023: $398 · 2024: $632 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,054 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.52 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $376.73 | 2020-2025 | Tremfya |
| Amgen INC. | $299.08 | 2020-2023 | Otezla |
| Incyte Corporation | $242.54 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $190.50 | 2019-2024 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $171.95 | 2019-2023 | |
| Dermavant Sciences, INC. | $166.67 | 2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $154.72 | 2021-2025 | Ilumya |
| Pfizer INC. | $99.17 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $89.63 | 2022-2024 | Sotyktu |
| Abbvie INC. | $87.95 | 2019-2022 | |
| Almirall LLC | $61.42 | 2019-2025 | Klisyri |
| Regeneron Healthcare Solutions, INC. | $50.12 | 2019-2022 | |
| Ucb, INC. | $50.01 | 2024-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $48.96 | 2019-2025 | Nemluvio |
| Leo Pharma INC. | $48.67 | 2019-2024 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $40.80 | 2020-2021 | |
| Genzyme Corporation | $40.06 | 2019-2024 | |
| Paratek Pharmaceuticals, INC. | $32.96 | 2022-2024 | Nuzyra |
| Mayne Pharma Commercial LLC | $29.36 | 2019-2023 | |
| Arcutis Biotherapeutics, INC. | $29.21 | 2023 | |
| Celgene Corporation | $26.94 | 2019 | |
| Mallinckrodt Hospital Products INC. | $26.76 | 2025 | Acthar |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $25.32 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $22.02 | 2019 | |
| Smith+Nephew, INC. | $20.05 | 2025 | Collagenase Santyl |
| Biofrontera INC. | $19.96 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Sandoz INC. | $19.42 | 2021 | |
| Bioventus LLC | $18.06 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.82 | 2024 | Spevigo |
| Mission Pharmacal Company | $14.52 | 2020 | |
| Botanix Sb INC | $13.53 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Mccrary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.